menu
    • menu
    [{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"Inactive rhomboid protein 2 (RHBDF2)","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Jiaotong University School of Medicine","sponsor":"Shanghai Xuhui District Mental Health Center | Shanghai Pudong Nanhui Mental Health Center | Suzhou Psychiatric Hospital | Second Xiangya Hospital, Central South University | Guangzhou Psychiatric Hospital | Shenzhen Fushan Biotech Co., Ltd. | Tianjin And","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"Inactive rhomboid protein 2 (RHBDF2)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Shanghai Jiaotong University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Jiaotong University School of Medicine \/ Shanghai Xuhui District Mental Health Center | Shanghai Pudong Nanhui Mental Health Center | Suzhou Psychiatric Hospital | Second Xiangya Hospital, Central South University | Guangzhou Psychiatric Hospital | Shenzhen Fushan Biotech Co., Ltd. | Tianjin And","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Jiaotong University School of Medicine \/ Shanghai Xuhui District Mental Health Center | Shanghai Pudong Nanhui Mental Health Center | Suzhou Psychiatric Hospital | Second Xiangya Hospital, Central South University | Guangzhou Psychiatric Hospital | Shenzhen Fushan Biotech Co., Ltd. | Tianjin And"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"Inactive rhomboid protein 2 (RHBDF2)","graph1":"Oncology","graph2":"Preclinical","graph3":"Evgen Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evgen Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Evgen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"University Of Dundee","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"||Inactive rhomboid protein 2 (RHBDF2)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evgen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evgen Pharma \/ University Of Dundee","highestDevelopmentStatusID":"9","companyTruncated":"Evgen Pharma \/ University Of Dundee"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"Inactive rhomboid protein 2 (RHBDF2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Evgen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evgen Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Evgen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"Inactive rhomboid protein 2 (RHBDF2)","graph1":"Oncology","graph2":"Preclinical","graph3":"Evgen Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evgen Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Evgen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Sulforaphane","moa":"||Inactive rhomboid protein 2 (RHBDF2)","graph1":"Oncology","graph2":"Preclinical","graph3":"Evgen Pharma","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Evgen Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Evgen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Specialty Health Care","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"Inactive rhomboid protein 2 (RHBDF2)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Sunshine Specialty Health Care","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Sunshine Specialty Health Care \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sunshine Specialty Health Care \/ Undisclosed"},{"orgOrder":0,"company":"Eastern Cooperative Oncology Group","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"Inactive rhomboid protein 2 (RHBDF2)","graph1":"Oncology","graph2":"Phase II","graph3":"Eastern Cooperative Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eastern Cooperative Oncology Group \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Eastern Cooperative Oncology Group \/ National Institutes of Health"},{"orgOrder":0,"company":"University of Rochester","sponsor":"University of Virginia | Nutramax Laboratories | National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"Inactive rhomboid protein 2 (RHBDF2)","graph1":"Nephrology","graph2":"Phase II","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Rochester \/ University of Virginia | Nutramax Laboratories | National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"8","companyTruncated":"University of Rochester \/ University of Virginia | Nutramax Laboratories | National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"University of Rochester School of Medicine & Dentistry","sponsor":"Evgen Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Sulforaphane","moa":"Inactive rhomboid protein 2 (RHBDF2)","graph1":"Nephrology","graph2":"Undisclosed","graph3":"University of Rochester School of Medicine & Dentistry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Rochester School of Medicine & Dentistry \/ Evgen Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Rochester School of Medicine & Dentistry \/ Evgen Pharma"},{"orgOrder":0,"company":"Broc Shot","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"Inactive rhomboid protein 2 (RHBDF2)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Broc Shot","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Broc Shot \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Broc Shot \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Oncology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Therapeutic Solutions \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Sulforaphane

    Menu

    Sulforaphane

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Broc Shot

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Broc Shot

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulforaphane

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Broc Shot Wins Seal Of Recognition From National Psoriasis Foundation

                            Details : Broc Shot (sulforaphane) is a natural, gentle and non-irritating option for those patients suffering from psoriasis-prone skin.

                            Product Name : Broc Shot

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 29, 2025

                            Lead Product(s) : Sulforaphane

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eastern Cooperative Oncology Group

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Eastern Cooperative Oncology Group

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulforaphane

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sulforaphane Supplement Effect On Melanoma Prevention In Patients with Prior Melanoma

                            Details : Sulforaphane is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 27, 2025

                            Lead Product(s) : Sulforaphane

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University of Rochester

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Rochester

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulforaphane

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : University of Virginia | Nutramax Laboratories | National Institute of Diabetes and Digestive and Kidney Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease

                            Details : Sulforaphane is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 04, 2023

                            Lead Product(s) : Sulforaphane

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : University of Virginia | Nutramax Laboratories | National Institute of Diabetes and Digestive and Kidney Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sunshine Specialty Health Care

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sunshine Specialty Health Care

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulforaphane

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients

                            Details : Sulforaphane is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 04, 2022

                            Lead Product(s) : Sulforaphane

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Shanghai Mental Health Center

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shanghai Mental Health Center

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulforaphane

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pilot Study on Effect of add-on Sulforaphane to SSRIs and Application of Niacin Skin Flush Response Test in ...

                            Details : Sulforaphane is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depressive Disorder, Major.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 08, 2021

                            Lead Product(s) : Sulforaphane

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Evgen Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Evgen Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulforaphane

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Publication Of Data On SFX-01 In Glioblastoma

                            Details : The in vitro data, in GBM cells and patient-derived glioma-initiating cells, show anti-tumour activity of the Company's lead asset SFX-01. In both models, SFX-01 reduced tumour growth substantially and demonstrated statistically significant improved surv...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 10, 2021

                            Lead Product(s) : Sulforaphane

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Therapeutic Solutions

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Therapeutic Solutions

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Therapeutic Solutions International Discovers and Files Patent on Novel Cellular Therapy Combination for Augme...

                            Details : JadiCells, as well as QuadraMune®, a commercially available nutraceutical developed by the Company have been shown to reduce lung scarring in other experiments.

                            Product Name : QuadraMune

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 22, 2021

                            Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Evgen Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Evgen Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $15.3 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Evgen Pharma Announces Placing and Open Offer to raise up to £11 million

                            Details : The net proceeds of the Fundraising are intended to be used to complete the formulation and scale up manufacturing of SFX-01 and other R&D nd general corporate purposes.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 02, 2021

                            Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $15.3 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Evgen Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Evgen Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulforaphane

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evgen Pharma Announces Positive Pre-Clinical Data in Glioma for Lead Asset SFX-01

                            Details : The data generated for SFX-01 in standard pre-clinical models and orthotopic models (where glioma cells are implanted in brain tissue representing a more disease-relevant model) show tumour shrinkage and significantly extended survival times.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 21, 2021

                            Lead Product(s) : Sulforaphane

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Evgen Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Evgen Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : University Of Dundee

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evgen Pharma Provides Patient Recruitment Update in STAR-COVID 19 Trial

                            Details : A total of 56 patients had been recruited and randomised to the STAR trial ("SFX-01 treatment for Acute Respiratory Infections").SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 19, 2021

                            Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : University Of Dundee

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth